4[1]Hantson L,Deweerdt W,De keyser J,et al. The European Stroke Scale[J]. Stroke,1994,25:2215-2219.
5[2]Memezawa H,Simith ML,Siesjo BK. Penumbral tissue salvaged by reperfusion following middle cerebral artery occlusion in rats[J]. Stroke,1992,23:552-567.
6[3]Del Zoppo GJ,Pessin MS,Mori E,et al. Thrombolytic intervention in acute thrombolic and embolic stroke[J]. Semin Neurol,1991,11:368-384.
7[4]The ECASS Study Grroup. Intravenous thrombolysis with recombinant tissue plasminogcn activator for acute hemispheric stroke[J]. JAMA,1995,274:1017-1025.
8[5]The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med,1995,333:1581-1592.
9[6]Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase,aspirin and combination of both in treatment of acute ischemic stroke[J]. Lancet,1995,346:1509-1514.
10Ueda T, Hatakeyama T, Kumon Y, et al. Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke, 1994, 25(2): 298-303.
5The national institute of neurological disease and strokert-PA stroke study group.Tissue plasminogen agents activator for acute ischemic stroke[J].N Eng J Med,1995,333(24):1581-1587.
6Steiner T,Bluhmki E,Kaste M,et al.The ECASS 3-hour cohort.Secondary analysis of ECASS data by time stratification.ECASS Study Group.European Cooperative Acute Stoke Study[J].Cerebrovasc Dis,1998,8(4):198-203.
7Hacke W,Bluhmki E,Steiner T,et al.Dichotomize defficacy end points and global end-point analysis appliedto the ECASS intention-to-treat data set:post hoc analysis of ECASS I[J].Stroke,1998,29(10):2073-2075.
8Stingele R,Bluhmki E,Hacke W.Bootstrap statistics of ECASS Ⅱ data:just another post hoc analysis of anegative stroke trial[J].Cerebrovasc Dis,2001,11(1):30-33.
